On January 6, 2026 OncoNano Medicine, Inc. ("OncoNano") reported a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) ("Gilead") to evaluate OncoNano’s ON-BOARD encapsulation technology with Gilead’s drug candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, OncoNano and Gilead will collaborate to evaluate the stability, selectivity and efficacy of Gilead’s drug candidate encapsulated by OncoNano’s ON-BOARD technology.

"Partnering with Gilead underscores the broad applicability of our ON-BOARD platform," said Kartik Krishnan, MD, PhD, CEO of OncoNano Medicine. "Our platform is designed to localize drug delivery into tumors with high spatial and temporal specificity. We believe it can complement Gilead’s oncology expertise to bring effective treatment options to patients."

Under the terms of the agreement, OncoNano will receive an upfront payment and is eligible to receive additional near-term preclinical milestones. OncoNano is also eligible to receive development, regulatory and commercial milestones, and royalties on net sales for the encapsulated asset. Gilead has the option to expand the collaboration by nominating an additional target for the ON-BOARD technology, in which case OncoNano would be eligible to receive up to an aggregate of $300 million, comprising the upfront payment and milestone payments, plus royalties.

(Press release, OncoNano Medicine, JAN 6, 2026, View Source [SID1234661788])